Kalaris Therapeutics, Inc. (KLRS) intrinsic value & 10-year financials
Kalaris Therapeutics, Inc. (KLRS) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.00
- Market cap
- $30.5M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -50.9%
- Free cash flow (FY2025)
- -$38.6M
KLRS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$43.4M | -$2.85 | -$38.6M | — | 399.8% |
| FY2024 | — | -$58.8M | -$3.91 | — | — | -194.4% |
| FY2023 | — | -$190.4M | -$0.61 | — | — | -182.5% |
| FY2022 | — | -$168.7M | -$0.73 | — | — | -176.5% |
| FY2021 | — | -$172.0M | -$0.91 | -$106.3M | — | -120.0% |
| FY2020 | — | -$69.8M | — | -$61.0M | — | -105.8% |
| FY2019 | $165.0K | -$23.8M | — | -$20.5M | -16182.4% | 22.9% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Kalaris Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Kalaris Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -29.2% ROIC.
Kalaris Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Kalaris Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.